Selected research
Market Analysis & Forecast
Global Personalized Psychiatry Market Analysis and Forecast 2026-2032
Market perspective
The global Personalized Psychiatry market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Personalized Psychiatry is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Personalized Psychiatry is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Personalized Psychiatry is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Personalized Psychiatry is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Personalized Psychiatry include COMPASS Pathways, Mindstrong Health, Pear Therapeutics, Cogito, Kaia Health, Sooma, GenoMind, Empatica and Akili Interactive, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Personalized Psychiatry, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Personalized Psychiatry, also provides the revenue of main regions and countries. Of the upcoming market potential for Personalized Psychiatry, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Personalized Psychiatry revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Personalized Psychiatry market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Personalized Psychiatry revenue, projected growth trends, production technology, application and end-user industry.
Personalized Psychiatry Segment by Company
COMPASS Pathways
Mindstrong Health
Pear Therapeutics
Cogito
Kaia Health
Sooma
GenoMind
Empatica
Akili Interactive
Neuroverse
Personalized Psychiatry Segment by Type
Depression and Anxiety
Bipolar Disorder
Addiction
Other
Personalized Psychiatry Segment by Application
Mental Health Professionals
Patients
Healthcare Providers
Personalized Psychiatry Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Personalized Psychiatry market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Personalized Psychiatry and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Personalized Psychiatry.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Personalized Psychiatry in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Personalized Psychiatry company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Personalized Psychiatry revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Depression and Anxiety
- Bipolar Disorder
- Addiction
- Other
Applications
- Mental Health Professionals
- Patients
- Healthcare Providers
Companies covered
- COMPASS Pathways
- Mindstrong Health
- Pear Therapeutics
- Cogito
- Kaia Health
- Sooma
- GenoMind
- Empatica
- Akili Interactive
- Neuroverse
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Personalized Psychiatry Market by Type
- 1.2.1 Global Personalized Psychiatry Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Depression and Anxiety
- 1.2.3 Bipolar Disorder
- 1.2.4 Addiction
- 1.2.5 Other
- 1.3 Personalized Psychiatry Market by Application
- 1.3.1 Global Personalized Psychiatry Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Mental Health Professionals
- 1.3.3 Patients
- 1.3.4 Healthcare Providers
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Personalized Psychiatry Market Dynamics
- 2.1 Personalized Psychiatry Industry Trends
- 2.2 Personalized Psychiatry Industry Drivers
- 2.3 Personalized Psychiatry Industry Opportunities and Challenges
- 2.4 Personalized Psychiatry Industry Restraints
3 Global Growth Perspective
- 3.1 Global Personalized Psychiatry Market Perspective (2021-2032)
- 3.2 Global Personalized Psychiatry Growth Trends by Region
- 3.2.1 Global Personalized Psychiatry Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Personalized Psychiatry Market Size by Region (2021-2026)
- 3.2.3 Global Personalized Psychiatry Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Personalized Psychiatry Revenue by Players
- 4.1.1 Global Personalized Psychiatry Revenue by Players (2021-2026)
- 4.1.2 Global Personalized Psychiatry Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Personalized Psychiatry Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Personalized Psychiatry Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Personalized Psychiatry Key Players Headquarters & Area Served
- 4.4 Global Personalized Psychiatry Players, Product Type & Application
- 4.5 Global Personalized Psychiatry Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Personalized Psychiatry Market CR5 and HHI
- 4.6.3 2025 Personalized Psychiatry Tier 1, Tier 2, and Tier 3
5 Personalized Psychiatry Market Size by Type
- 5.1 Global Personalized Psychiatry Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Personalized Psychiatry Revenue by Type (2021-2032)
- 5.3 Global Personalized Psychiatry Revenue Market Share by Type (2021-2032)
6 Personalized Psychiatry Market Size by Application
- 6.1 Global Personalized Psychiatry Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Personalized Psychiatry Revenue by Application (2021-2032)
- 6.3 Global Personalized Psychiatry Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 COMPASS Pathways
- 7.1.1 COMPASS Pathways Company Information
- 7.1.2 COMPASS Pathways Business Overview
- 7.1.3 COMPASS Pathways Personalized Psychiatry Revenue and Gross Margin (2021-2026)
- 7.1.4 COMPASS Pathways Personalized Psychiatry Product Portfolio
- 7.1.5 COMPASS Pathways Recent Developments
- 7.2 Mindstrong Health
- 7.2.1 Mindstrong Health Company Information
- 7.2.2 Mindstrong Health Business Overview
- 7.2.3 Mindstrong Health Personalized Psychiatry Revenue and Gross Margin (2021-2026)
- 7.2.4 Mindstrong Health Personalized Psychiatry Product Portfolio
- 7.2.5 Mindstrong Health Recent Developments
- 7.3 Pear Therapeutics
- 7.3.1 Pear Therapeutics Company Information
- 7.3.2 Pear Therapeutics Business Overview
- 7.3.3 Pear Therapeutics Personalized Psychiatry Revenue and Gross Margin (2021-2026)
- 7.3.4 Pear Therapeutics Personalized Psychiatry Product Portfolio
- 7.3.5 Pear Therapeutics Recent Developments
- 7.4 Cogito
- 7.4.1 Cogito Company Information
- 7.4.2 Cogito Business Overview
- 7.4.3 Cogito Personalized Psychiatry Revenue and Gross Margin (2021-2026)
- 7.4.4 Cogito Personalized Psychiatry Product Portfolio
- 7.4.5 Cogito Recent Developments
- 7.5 Kaia Health
- 7.5.1 Kaia Health Company Information
- 7.5.2 Kaia Health Business Overview
- 7.5.3 Kaia Health Personalized Psychiatry Revenue and Gross Margin (2021-2026)
- 7.5.4 Kaia Health Personalized Psychiatry Product Portfolio
- 7.5.5 Kaia Health Recent Developments
- 7.6 Sooma
- 7.6.1 Sooma Company Information
- 7.6.2 Sooma Business Overview
- 7.6.3 Sooma Personalized Psychiatry Revenue and Gross Margin (2021-2026)
- 7.6.4 Sooma Personalized Psychiatry Product Portfolio
- 7.6.5 Sooma Recent Developments
- 7.7 GenoMind
- 7.7.1 GenoMind Company Information
- 7.7.2 GenoMind Business Overview
- 7.7.3 GenoMind Personalized Psychiatry Revenue and Gross Margin (2021-2026)
- 7.7.4 GenoMind Personalized Psychiatry Product Portfolio
- 7.7.5 GenoMind Recent Developments
- 7.8 Empatica
- 7.8.1 Empatica Company Information
- 7.8.2 Empatica Business Overview
- 7.8.3 Empatica Personalized Psychiatry Revenue and Gross Margin (2021-2026)
- 7.8.4 Empatica Personalized Psychiatry Product Portfolio
- 7.8.5 Empatica Recent Developments
- 7.9 Akili Interactive
- 7.9.1 Akili Interactive Company Information
- 7.9.2 Akili Interactive Business Overview
- 7.9.3 Akili Interactive Personalized Psychiatry Revenue and Gross Margin (2021-2026)
- 7.9.4 Akili Interactive Personalized Psychiatry Product Portfolio
- 7.9.5 Akili Interactive Recent Developments
- 7.10 Neuroverse
- 7.10.1 Neuroverse Company Information
- 7.10.2 Neuroverse Business Overview
- 7.10.3 Neuroverse Personalized Psychiatry Revenue and Gross Margin (2021-2026)
- 7.10.4 Neuroverse Personalized Psychiatry Product Portfolio
- 7.10.5 Neuroverse Recent Developments
8 North America
- 8.1 North America Personalized Psychiatry Revenue (2021-2032)
- 8.2 North America Personalized Psychiatry Revenue by Type (2021-2032)
- 8.2.1 North America Personalized Psychiatry Revenue by Type (2021-2026)
- 8.2.2 North America Personalized Psychiatry Revenue by Type (2027-2032)
- 8.3 North America Personalized Psychiatry Revenue Share by Type (2021-2032)
- 8.4 North America Personalized Psychiatry Revenue by Application (2021-2032)
- 8.4.1 North America Personalized Psychiatry Revenue by Application (2021-2026)
- 8.4.2 North America Personalized Psychiatry Revenue by Application (2027-2032)
- 8.5 North America Personalized Psychiatry Revenue Share by Application (2021-2032)
- 8.6 North America Personalized Psychiatry Revenue by Country
- 8.6.1 North America Personalized Psychiatry Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Personalized Psychiatry Revenue by Country (2021-2026)
- 8.6.3 North America Personalized Psychiatry Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Personalized Psychiatry Revenue (2021-2032)
- 9.2 Europe Personalized Psychiatry Revenue by Type (2021-2032)
- 9.2.1 Europe Personalized Psychiatry Revenue by Type (2021-2026)
- 9.2.2 Europe Personalized Psychiatry Revenue by Type (2027-2032)
- 9.3 Europe Personalized Psychiatry Revenue Share by Type (2021-2032)
- 9.4 Europe Personalized Psychiatry Revenue by Application (2021-2032)
- 9.4.1 Europe Personalized Psychiatry Revenue by Application (2021-2026)
- 9.4.2 Europe Personalized Psychiatry Revenue by Application (2027-2032)
- 9.5 Europe Personalized Psychiatry Revenue Share by Application (2021-2032)
- 9.6 Europe Personalized Psychiatry Revenue by Country
- 9.6.1 Europe Personalized Psychiatry Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Personalized Psychiatry Revenue by Country (2021-2026)
- 9.6.3 Europe Personalized Psychiatry Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Personalized Psychiatry Revenue (2021-2032)
- 10.2 China Personalized Psychiatry Revenue by Type (2021-2032)
- 10.2.1 China Personalized Psychiatry Revenue by Type (2021-2026)
- 10.2.2 China Personalized Psychiatry Revenue by Type (2027-2032)
- 10.3 China Personalized Psychiatry Revenue Share by Type (2021-2032)
- 10.4 China Personalized Psychiatry Revenue by Application (2021-2032)
- 10.4.1 China Personalized Psychiatry Revenue by Application (2021-2026)
- 10.4.2 China Personalized Psychiatry Revenue by Application (2027-2032)
- 10.5 China Personalized Psychiatry Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Personalized Psychiatry Revenue (2021-2032)
- 11.2 Asia Personalized Psychiatry Revenue by Type (2021-2032)
- 11.2.1 Asia Personalized Psychiatry Revenue by Type (2021-2026)
- 11.2.2 Asia Personalized Psychiatry Revenue by Type (2027-2032)
- 11.3 Asia Personalized Psychiatry Revenue Share by Type (2021-2032)
- 11.4 Asia Personalized Psychiatry Revenue by Application (2021-2032)
- 11.4.1 Asia Personalized Psychiatry Revenue by Application (2021-2026)
- 11.4.2 Asia Personalized Psychiatry Revenue by Application (2027-2032)
- 11.5 Asia Personalized Psychiatry Revenue Share by Application (2021-2032)
- 11.6 Asia Personalized Psychiatry Revenue by Country
- 11.6.1 Asia Personalized Psychiatry Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Personalized Psychiatry Revenue by Country (2021-2026)
- 11.6.3 Asia Personalized Psychiatry Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Personalized Psychiatry Revenue (2021-2032)
- 12.2 SAMEA Personalized Psychiatry Revenue by Type (2021-2032)
- 12.2.1 SAMEA Personalized Psychiatry Revenue by Type (2021-2026)
- 12.2.2 SAMEA Personalized Psychiatry Revenue by Type (2027-2032)
- 12.3 SAMEA Personalized Psychiatry Revenue Share by Type (2021-2032)
- 12.4 SAMEA Personalized Psychiatry Revenue by Application (2021-2032)
- 12.4.1 SAMEA Personalized Psychiatry Revenue by Application (2021-2026)
- 12.4.2 SAMEA Personalized Psychiatry Revenue by Application (2027-2032)
- 12.5 SAMEA Personalized Psychiatry Revenue Share by Application (2021-2032)
- 12.6 SAMEA Personalized Psychiatry Revenue by Country
- 12.6.1 SAMEA Personalized Psychiatry Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Personalized Psychiatry Revenue by Country (2021-2026)
- 12.6.3 SAMEA Personalized Psychiatry Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst